Karyopharm Therapeutics Inc. [NASDAQ: KPTI] plunged by -$0.12 during the normal trading session on Friday and reaching a high of $10.64 during the day while it closed the day at $10.51. The company report on July 1, 2021 that Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that in connection with the hiring of Ms. Sohanya Cheng, Senior Vice President, Sales and Commercial Operations, the Compensation Committee of Karyopharm’s Board of Directors granted a stock option to purchase 125,000 shares of Karyopharm’s common stock to Ms. Cheng, with a grant date of June 30, 2021. The stock option was granted as an inducement material to Ms. Cheng’s entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4). In the event that the services of Ms. Cheng are terminated by Karyopharm without cause prior to the first vesting of the stock option granted to Ms. Cheng, then the number of shares underlying the stock option that is scheduled to vest on the first anniversary of Ms. Cheng’s employment commencement date will vest upon her termination date.
The Compensation Committee also granted stock options to purchase an aggregate of 50,700 shares of Karyopharm’s common stock to 10 additional newly-hired employees, with a grant date of June 30, 2021. The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
Karyopharm Therapeutics Inc. stock has also loss -4.37% of its value over the past 7 days. However, KPTI stock has declined by -5.40% in the 3 months of the year. Over the past six months meanwhile, it has lost -32.11% and lost -32.11% year-on date.
The market cap for KPTI stock reached $798.23 million, with 74.52 million shares outstanding and 67.71 million shares in the current float. Compared to the average trading volume of 1.61M shares, KPTI reached a trading volume of 758980 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Karyopharm Therapeutics Inc. [KPTI]:
Morgan Stanley have made an estimate for Karyopharm Therapeutics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on July 02, 2020. While these analysts kept the previous recommendation, Barclays raised their target price to Overweight. The new note on the price target was released on March 04, 2020, representing the official price target for Karyopharm Therapeutics Inc. stock. On July 23, 2019, analysts increased their price target for KPTI shares from 8 to 16.
The Average True Range (ATR) for Karyopharm Therapeutics Inc. is set at 0.43, with the Price to Sales ratio for KPTI stock in the period of the last 12 months amounting to 7.05.
KPTI stock trade performance evaluation
Karyopharm Therapeutics Inc. [KPTI] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.37. With this latest performance, KPTI shares gained by 13.62% in over the last four-week period, additionally sinking by -32.11% over the last 6 months – not to mention a drop of -46.68% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for KPTI stock in for the last two-week period is set at 55.87, with the RSI for the last a single of trading hit 54.68, and the three-weeks RSI is set at 54.70 for Karyopharm Therapeutics Inc. [KPTI]. The present Moving Average for the last 50 days of trading for this stock 9.61, while it was recorded at 10.49 for the last single week of trading, and 13.15 for the last 200 days.
Karyopharm Therapeutics Inc. [KPTI]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Karyopharm Therapeutics Inc. [KPTI] shares currently have an operating margin of -159.00 and a Gross Margin at +96.60. Karyopharm Therapeutics Inc.’s Net Margin is presently recorded at -181.59.
Return on Total Capital for KPTI is now -96.50, given the latest momentum, and Return on Invested Capital for the company is -111.33. Return on Equity for this stock declined to -391.29, with Return on Assets sitting at -64.56. When it comes to the capital structure of this company, Karyopharm Therapeutics Inc. [KPTI] has a Total Debt to Total Equity ratio set at 259.43. Additionally, KPTI Total Debt to Total Capital is recorded at 72.18, with Total Debt to Total Assets ending up at 41.89. Long-Term Debt to Equity for the company is recorded at 255.63, with the Long-Term Debt to Total Capital now at 71.12.
Reflecting on the efficiency of the workforce at the company, Karyopharm Therapeutics Inc. [KPTI] managed to generate an average of -$454,336 per employee. Receivables Turnover for the company is 10.42 with a Total Asset Turnover recorded at a value of 0.36.Karyopharm Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.10 and a Current Ratio set at 4.10.
Karyopharm Therapeutics Inc. [KPTI]: Insider Ownership positions
There are presently around $632 million, or 82.40% of KPTI stock, in the hands of institutional investors. The top three institutional holders of KPTI stocks are: BLACKROCK INC. with ownership of 7,749,757, which is approximately 3.674% of the company’s market cap and around 3.20% of the total institutional ownership; PALO ALTO INVESTORS LP, holding 5,363,652 shares of the stock with an approximate value of $56.37 million in KPTI stocks shares; and STATE STREET CORP, currently with $56.04 million in KPTI stock with ownership of nearly -0.142% of the company’s market capitalization.
Positions in Karyopharm Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 85 institutional holders increased their position in Karyopharm Therapeutics Inc. [NASDAQ:KPTI] by around 10,062,869 shares. Additionally, 84 investors decreased positions by around 13,779,675 shares, while 26 investors held positions by with 36,255,257 shares. The mentioned changes placed institutional holdings at 60,097,801 shares, according to the latest SEC report filing. KPTI stock had 27 new institutional investments in for a total of 2,742,266 shares, while 26 institutional investors sold positions of 1,727,127 shares during the same period.